欢迎访问《现代生物医学进展》编辑部！

目的：研究甲亢低骨量患者131I治疗后干预治疗的效果。方法：对100 例甲亢低骨量患者，随机分为两组：A 组50 例，131I治疗后口服钙尔奇D 及罗盖全治疗；B 组50 例，131I 治疗后骨质自然恢复。另设C 组50 例为正常对照组。于131I治疗前、治疗后3、 6 及12 个月测定A、B 两组骨密度（BMD），观察其骨质变化并评价治疗效果。结果：（1）A 组随治疗时间延长BMD 逐渐升高，具有一定的规律性，腰椎（L2-4）骨密度3 个月提高明显（t= -2.111，P=0.04）且12 个月时达到与C 组无统计学差异（t= -2.290，P=0. 202）。（2）B组3 个月时腰椎BMD 有所降低，12 个月时升高明显（股骨颈t= -2.327，P=0.043；腰椎（L2-4）t= -2.798，P=0.000）。（3） 6 个月时两组腰椎骨密度改善幅度出现统计学差异（t= -2.416，P=0.018），12 个月时差异显著(t= -3.259，P=0.002)。结论：131I联合钙尔奇D 与罗盖全治疗甲亢低骨量患者，其恢复时间及疗效均用131I 治疗，能有效防止骨量的进一步下降及减少骨质疏松症的发生。

英文摘要:

Objective:To investigate the effect of intervention therapy in patients of hyperthyroidism with low bone mass after 131I treatment.Methods:100 cases of hyperthyroidism patients with low bone mass, were randomly divided into two groups: 50 cases in group A, taking Caltrate D and Rocaltrol after 131I treatment; 50 cases in group B, bone natural recovery after 131I treatment. Another 30 cases in group C as normal control group. Before 131I treatment and after 3, 6 and 12 months, groups A and B were measured to observe the changes of bone mineral density (BMD) and evaluate the effect of intervention therapy.Results:(1) Group A: the BMD increased gradually and had a regular change. The lumbar vertebra (L2-4) reached to the level which there was no significant difference compared with that of group C after 12 months treatment (P=0.202>0.05). (2) Group B: the L2-4 had little decrease 3 months later, but increased evidently after 12 months (femoral neck: P=0.043; L2-4: P=0.000).(3) The changing extent of the L2-4 of these two groups appeared significant difference after 6 months (t= -2.416, P=0.018) and the disparity was more evident after 12 months (t= -3.259, P=0.002).Conclusion:The recovery time and curative effect of using 131I combined with Caltrate D and Rocaltrol is superior to using the single 131I treatment. The combined cure can effectively prevent further decrease in bone mass and reduce the occurrence of osteoporosis.

查看全文查看/发表评论下载PDF阅读器

关闭